Barrack, Rodos & Bacine Files Antitrust Complaint Against Manufacturers of Generic Pravastatin Sodium

1/4/2017 - Barrack, Rodos & Bacine filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against a number of manufacturers of generic pravastatin sodium, a commonly prescribed drug used to lower cholesterol and triglycerides in the blood.  The proposed class action alleges that the defendants engaged in an illegal price-fixing conspiracy which caused purchasers of generic pravastatin sodium to pay artificially inflated prices for the drug.  Generic versions of pravastatin sodium have been on the market for years, and for most of that time have been priced significantly lower than their branded counterparts.  Recently, however, generic pravastatin sodium has experienced unprecedented price increases.  The complaint alleges that these price hikes were not the result of competitive market forces but were the result of defendants’ illegal conspiracy.  The complaint also alleges that defendants orchestrated their conspiracy through secret communications and meetings, both in private and at public events such as trade association meetings.  The complaint seeks equitable and injunctive relief on behalf of a nationwide class of persons and entities in the United States who purchased, paid and/or provided reimbursement for some or all of the purchase price paid for defendants’ generic pravastatin sodium from October 1, 2013 through the present.  The complaint also seeks damages on behalf of entities and persons in certain identified states pursuant to those states’ antitrust, unfair competition, and consumer protection laws.  The case is captioned Detectives Endowment Association of the City of New York v. Actavis Holdco U.S., Inc., et al., Civil Action No. 17-cv-00013-TON (E.D. Pa.). 

Please contact BR&B partners Jeffrey Gittleman (jgittleman@barrack.com) or Jeffrey Barrack (jbarrack@barrack.com) with any questions.